Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech
Go back to Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech| (NASDAQ: JUNS) | Delayed: 0.24 +0.01 (4.35%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.23 | 52 Week High | $ | |||
| Open | $0.23 | 52 Week Low | $ | |||
| Day High | $0.26 | P/E | N/A | |||
| Day Low | $0.22 | EPS | $ | |||
| Volume | 5,291,794 | |||||
| Medmark Group Inc New (AMEX: MDMA) | Delayed: 0.00 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.00 | 52 Week High | $0.00 | |||
| Open | $0.00 | 52 Week Low | $0.00 | |||
| Day High | $0.00 | P/E | N/A | |||
| Day Low | $0.00 | EPS | $0.00 | |||
| Volume | 0 | |||||
| (AMEX: MDXXF) | Delayed: 0.11 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.11 | 52 Week High | $ | |||
| Open | $0.11 | 52 Week Low | $ | |||
| Day High | $0.11 | P/E | N/A | |||
| Day Low | $0.11 | EPS | $ | |||
| Volume | 850,183 | |||||
